TWI269655B - Ciclesonide-containing aqueous pharmaceutical composition - Google Patents
Ciclesonide-containing aqueous pharmaceutical composition Download PDFInfo
- Publication number
- TWI269655B TWI269655B TW089121991A TW89121991A TWI269655B TW I269655 B TWI269655 B TW I269655B TW 089121991 A TW089121991 A TW 089121991A TW 89121991 A TW89121991 A TW 89121991A TW I269655 B TWI269655 B TW I269655B
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- aqueous pharmaceutical
- weight
- composition according
- water
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 44
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 title claims abstract 6
- 229960003728 ciclesonide Drugs 0.000 title claims abstract 6
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 20
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 20
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 20
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000012736 aqueous medium Substances 0.000 claims abstract description 10
- 239000002245 particle Substances 0.000 claims abstract description 8
- 239000007787 solid Substances 0.000 claims abstract description 7
- 229920002678 cellulose Polymers 0.000 claims description 20
- 239000001913 cellulose Substances 0.000 claims description 20
- 235000010980 cellulose Nutrition 0.000 claims description 20
- 239000000758 substrate Substances 0.000 claims description 19
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 15
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims description 10
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims description 10
- 229920003169 water-soluble polymer Polymers 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 229920000151 polyglycol Polymers 0.000 claims description 3
- 239000010695 polyglycol Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims description 2
- 238000007639 printing Methods 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 101150052500 cic-1 gene Proteins 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 15
- 238000011084 recovery Methods 0.000 abstract description 14
- 230000007423 decrease Effects 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 9
- 229940049964 oleate Drugs 0.000 description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 7
- 229950008882 polysorbate Drugs 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- -1 glyceryl monostearate Ester Chemical class 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- OJHZNMVJJKMFGX-BWCYBWMMSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC OJHZNMVJJKMFGX-BWCYBWMMSA-N 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000307 polymer substrate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29818699 | 1999-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI269655B true TWI269655B (en) | 2007-01-01 |
Family
ID=17856339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW089121991A TWI269655B (en) | 1999-10-20 | 2000-10-19 | Ciclesonide-containing aqueous pharmaceutical composition |
Country Status (35)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR026073A1 (es) * | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
| HK1080365B (zh) * | 2002-07-02 | 2008-11-28 | Astrazeneca Ab | 含有环索奈德的无菌水性混悬剂 |
| PT1545548E (pt) | 2002-08-30 | 2010-09-02 | Nycomed Gmbh | Utilização da combinação de ciclesonida e anti-histamínicos para o tratamento de rinite alérgica |
| AU2003293833B2 (en) | 2002-12-12 | 2009-10-01 | Covis Pharma B.V. | Combination medicament |
| MY143936A (en) | 2003-03-27 | 2011-07-29 | Nycomed Gmbh | Process for preparing crystalline ciclesonide with defined particle size |
| PT1670482E (pt) | 2003-09-16 | 2014-03-12 | Takeda Gmbh | Utilização de ciclesonida para o tratamento de doenças respiratórias |
| PE20050941A1 (es) * | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
| CA2588433A1 (en) * | 2004-11-17 | 2006-05-26 | Michael R. Robinson | Steroid formulation and methods of treatment using same |
| JP5661985B2 (ja) * | 2006-12-27 | 2015-01-28 | 帝人ファーマ株式会社 | 無菌性水性懸濁製剤 |
| SI2262506T1 (sl) | 2008-03-11 | 2014-07-31 | Alcon Research, Ltd. | Močno flokulirane suspenzije triamcinolon acetonida z nizko viskoznostjo za intravitrealno injekcijo |
| WO2013024070A1 (en) | 2011-08-18 | 2013-02-21 | Nycomed Gmbh | Pharmaceutical aerosol product for administration by oral or nasal inhalation |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271143A (en) | 1978-01-25 | 1981-06-02 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
| CH657779A5 (de) | 1982-10-05 | 1986-09-30 | Sandoz Ag | Galenische zusammensetzungen enthaltend calcitonin. |
| IL70489A0 (en) | 1982-12-29 | 1984-03-30 | Armour Pharma | Pharmaceutical compositions containing calcitonin |
| JPS59163313A (ja) | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| EP0501523B1 (en) | 1983-11-14 | 1997-04-09 | Columbia Laboratories, Inc. | Bioadhesive compositions |
| GB8515132D0 (en) | 1985-06-14 | 1985-07-17 | British Nuclear Fuels Plc | Measuring photosynthetic activities of plants |
| US5179079A (en) | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
| MY102411A (en) | 1986-12-23 | 1992-06-17 | Ciba Geigy Ag | Nasal solutions |
| JPH0744940B2 (ja) | 1986-12-24 | 1995-05-17 | ライオン株式会社 | 口腔貼付用基材 |
| US4802967A (en) | 1987-04-08 | 1989-02-07 | Andus Corporation | Surface treatment of polymers |
| JPS63303931A (ja) | 1987-06-05 | 1988-12-12 | Sumitomo Pharmaceut Co Ltd | 経鼻投与用成長ホルモン放出活性物質製剤 |
| US4788220A (en) | 1987-07-08 | 1988-11-29 | American Home Products Corporation (Del.) | Pediatric ibuprofen compositions |
| US5188826A (en) | 1988-02-08 | 1993-02-23 | Insite Vision Incorporated | Topical ophthalmic suspensions |
| US5192535A (en) | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
| US5776493A (en) | 1989-07-14 | 1998-07-07 | Alza Corporation | Oral osmotic device for delivery of nystatin with hydrogel driving member |
| EP0431719B1 (en) | 1989-10-31 | 1994-11-09 | Columbia Laboratories, Inc. | Vaginal tissue moisturizing composition |
| US5147654A (en) | 1990-07-23 | 1992-09-15 | Alza Corporation | Oral osmotic device for delivering nicotine |
| JPH078806B2 (ja) | 1990-08-16 | 1995-02-01 | 旭化成工業株式会社 | カルシトニン類含有経鼻投与用乳剤 |
| GB9102579D0 (en) | 1991-01-24 | 1991-03-27 | Glaxo Group Ltd | Compositions |
| GB9103824D0 (en) | 1991-02-23 | 1991-04-10 | Fisons Ag | Formulation |
| KR100247441B1 (ko) | 1991-04-03 | 2000-04-01 | 자클린 비. 슈라고 | 트롬복산 레벨 억제용 경피투여 약제학적 아스피린 조성물 |
| IT1250691B (it) * | 1991-07-22 | 1995-04-21 | Giancarlo Santus | Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac. |
| US5200195A (en) | 1991-12-06 | 1993-04-06 | Alza Corporation | Process for improving dosage form delivery kinetics |
| JP2860729B2 (ja) | 1992-03-10 | 1999-02-24 | エスエス製薬株式会社 | プラノプロフェン懸濁シロップ剤 |
| CA2101126A1 (en) | 1992-08-03 | 1994-02-04 | Yasushi Morita | Preparation for local treatment |
| JP3047948B2 (ja) | 1992-12-07 | 2000-06-05 | 株式会社ツムラ | ペプチド類経鼻投与用組成物 |
| US5340572A (en) | 1993-02-08 | 1994-08-23 | Insite Vision Incorporated | Alkaline ophthalmic suspensions |
| US5409703A (en) | 1993-06-24 | 1995-04-25 | Carrington Laboratories, Inc. | Dried hydrogel from hydrophilic-hygroscopic polymer |
| JP2787131B2 (ja) | 1993-07-30 | 1998-08-13 | 千寿製薬株式会社 | 水性懸濁液剤 |
| US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| JP3781792B2 (ja) | 1993-12-27 | 2006-05-31 | 千寿製薬株式会社 | ジフルプレドナート含有点眼用懸濁液剤 |
| JPH07188059A (ja) | 1993-12-28 | 1995-07-25 | Rohto Pharmaceut Co Ltd | 歯周病治療剤 |
| RU2102979C1 (ru) | 1994-07-18 | 1998-01-27 | Панкрушева Татьяна Александровна | Средство для лечения гнойно-воспалительных процессов кожи и слизистых оболочек различной этиологии |
| US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| WO1997001337A1 (en) | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
| JP3098401B2 (ja) | 1995-07-12 | 2000-10-16 | 株式会社エルティーティー研究所 | 経鼻投与用製剤 |
| JP2791317B2 (ja) | 1995-12-26 | 1998-08-27 | 株式会社三和化学研究所 | 多層フィルム製剤 |
| WO1997031626A1 (en) | 1996-02-27 | 1997-09-04 | Teijin Limited | Powdery composition for nasal administration |
| US5976573A (en) | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
| US5955097A (en) | 1996-10-18 | 1999-09-21 | Virotex Corporation | Pharmaceutical preparation applicable to mucosal surfaces and body tissues |
| IT1286496B1 (it) | 1996-11-20 | 1998-07-15 | Leetrim Ltd Dublin | Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria |
| FR2756739B1 (fr) | 1996-12-05 | 2000-04-28 | Astra Ab | Nouvelle formulation de budesonide |
| SE9604486D0 (sv) | 1996-12-05 | 1996-12-05 | Astra Ab | Novel formulation |
| TW503113B (en) | 1997-01-16 | 2002-09-21 | Senju Pharma Co | Aqueous suspension for nasal administration |
| US6120752A (en) | 1997-05-21 | 2000-09-19 | 3M Innovative Properties Company | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
| JPH1121229A (ja) | 1997-06-30 | 1999-01-26 | Kyoto Yakuhin Kogyo Kk | 抗真菌性外用製剤およびその製造方法 |
| JPH11130658A (ja) | 1997-10-30 | 1999-05-18 | Teijin Ltd | 水性懸濁医薬品組成物 |
| JP3386349B2 (ja) | 1997-10-30 | 2003-03-17 | 帝人株式会社 | 水性懸濁医薬品組成物 |
| JP3386348B2 (ja) | 1997-10-30 | 2003-03-17 | 帝人株式会社 | 鼻腔内投与用水性懸濁製剤 |
| SE9704186D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| CA2318642A1 (en) * | 1998-01-22 | 1999-07-29 | Santen Pharmaceutical Co., Ltd. | Fluorometholone ophthalmic suspension |
| SE514128C2 (sv) * | 1998-03-17 | 2001-01-08 | Pharmalink Ab | Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit |
| TWI243687B (en) | 1998-04-21 | 2005-11-21 | Teijin Ltd | Pharmaceutical composition for application to mucosa |
| US6124268A (en) * | 1999-02-17 | 2000-09-26 | Natreon Inc. | Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof |
| RU11829U1 (ru) | 1999-05-05 | 1999-11-16 | Специальное конструкторское бюро транспортного машиностроения (ОАО Спецмаш) | Рабочая площадка для буровых установок |
| AR026072A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa |
| EP1142565A4 (en) | 1999-10-20 | 2004-03-17 | Teijin Ltd | AQUEOUS THERAPEUTIC COMPOSITIONS |
| AR026073A1 (es) * | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
-
2000
- 2000-10-18 AR ARP000105474A patent/AR026073A1/es not_active Application Discontinuation
- 2000-10-19 PE PE2000001119A patent/PE20010713A1/es not_active IP Right Cessation
- 2000-10-19 TW TW089121991A patent/TWI269655B/zh not_active IP Right Cessation
- 2000-10-19 MY MYPI20004916A patent/MY121175A/en unknown
- 2000-10-19 CO CO00079609A patent/CO5251406A1/es active IP Right Grant
- 2000-10-20 BR BRPI0014880A patent/BRPI0014880B8/pt not_active IP Right Cessation
- 2000-10-20 HU HU0203756A patent/HU228894B1/hu unknown
- 2000-10-20 CN CNB00814253XA patent/CN1198623C/zh not_active Expired - Lifetime
- 2000-10-20 ES ES00969967T patent/ES2223595T3/es not_active Expired - Lifetime
- 2000-10-20 SK SK693-2002A patent/SK286194B6/sk not_active IP Right Cessation
- 2000-10-20 CA CA002388325A patent/CA2388325C/en not_active Expired - Fee Related
- 2000-10-20 EA EA200200383A patent/EA005201B1/ru not_active IP Right Cessation
- 2000-10-20 WO PCT/JP2000/007351 patent/WO2001028563A1/en not_active Ceased
- 2000-10-20 JP JP2001531393A patent/JP4856338B2/ja not_active Expired - Lifetime
- 2000-10-20 HR HR20020345A patent/HRP20020345B1/xx not_active IP Right Cessation
- 2000-10-20 EP EP00969967A patent/EP1227817B1/en not_active Expired - Lifetime
- 2000-10-20 IL IL14872500A patent/IL148725A0/xx active IP Right Grant
- 2000-10-20 SI SI200030483T patent/SI1227817T1/xx unknown
- 2000-10-20 AU AU79532/00A patent/AU776587B2/en not_active Expired
- 2000-10-20 RS YUP-281/02A patent/RS50345B/sr unknown
- 2000-10-20 KR KR1020027004994A patent/KR100705372B1/ko not_active Expired - Lifetime
- 2000-10-20 PL PL356190A patent/PL197537B1/pl unknown
- 2000-10-20 AT AT00969967T patent/ATE270107T1/de active
- 2000-10-20 TR TR2002/00831T patent/TR200200831T2/xx unknown
- 2000-10-20 PT PT00969967T patent/PT1227817E/pt unknown
- 2000-10-20 US US10/110,632 patent/US8383611B1/en not_active Expired - Fee Related
- 2000-10-20 CZ CZ20021284A patent/CZ297780B6/cs not_active IP Right Cessation
- 2000-10-20 MX MXPA02003975A patent/MXPA02003975A/es active IP Right Grant
- 2000-10-20 DE DE60011924T patent/DE60011924T2/de not_active Expired - Lifetime
- 2000-10-20 DK DK00969967T patent/DK1227817T3/da active
- 2000-10-20 ME MEP-2008-857A patent/ME00568B/me unknown
- 2000-10-20 NZ NZ518299A patent/NZ518299A/en not_active IP Right Cessation
-
2002
- 2002-03-14 BG BG106517A patent/BG65799B1/bg unknown
- 2002-03-17 IL IL148725A patent/IL148725A/en unknown
- 2002-04-18 ZA ZA200203078A patent/ZA200203078B/xx unknown
- 2002-04-19 NO NO20021866A patent/NO327379B1/no not_active IP Right Cessation
-
2012
- 2012-11-29 US US13/688,659 patent/US20130095146A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI269655B (en) | Ciclesonide-containing aqueous pharmaceutical composition | |
| TW538039B (en) | Neutral S-omeprazole in a form or b form, process for preparing the same, and pharmaceutical composition comprising the same | |
| TW402501B (en) | Oral liquid alendronate formulations | |
| KR101680175B1 (ko) | 릴루졸 수성 현탁액 | |
| CA2285580A1 (en) | Gastroretentive controlled release microspheres for improved drug delivery | |
| TW200803902A (en) | Compositions and methods using proton pump inhibitors | |
| JPH01503534A (ja) | マイクロカプセルを含有する医薬調合物 | |
| JPS62298533A (ja) | 高コレステロ−ル血症治療薬およびその製造方法 | |
| JP3942827B2 (ja) | ジプラシドン懸濁剤 | |
| TW403658B (en) | Granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation | |
| WO2001028517A1 (fr) | Compositions therapeutiques aqueuses | |
| JPH06128147A (ja) | 水難溶性薬品の溶解性改善方法およびそれにより得られた薬品組成物 | |
| JPH04288013A (ja) | 懸濁シロップ剤 | |
| TW200841887A (en) | Intravenous administration of water soluble analgesic formulations | |
| JP2001294528A (ja) | アシクロビル懸濁シロップ剤 | |
| CN106692039A (zh) | 阿戈美拉汀口服液体制剂及其制备方法和应用 | |
| TW304881B (enExample) | ||
| JP2006131619A (ja) | 点鼻用懸濁水性液剤 | |
| JPWO2001028517A1 (ja) | 水性医薬品組成物 | |
| HK1051003B (zh) | 含环索奈德的含水药物组合物 | |
| HK1037544A (en) | Aqueous medicinal compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |